7 Jan 2014 17:27
7 January 2014
The following amendment has been made to the ' SEC filings available on Company's web site' announcement released on 7 January 2014 at 4:54 under RNS No 1212X.
The notes to editors regarding Chubeworkx / en10 Global Limited was incorrectly included and has now been removed.
All other details remain unchanged.
The full amended text is shown below.
7 January 2014
Akers Biosciences, Inc.
("ABI" or the "Company")
SEC filings available on Company's web site
Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that, further to its previous announcements regarding the proposed listing of the Company's common shares (the "Securities") on The NASDAQ Capital Market ("NASDAQ") and the concurrent registered public offering (the "Offering"), all the amendments to the Company's S-1 filing are available on the Company's web site (at http://ir.akersbiosciences.com/sec.cfm) together with the Free Writing Prospectus (FWP), or presentation, which has been filed with the SEC and will be used during the marketing process.
The Offering is subject to market and other conditions, and there can be no assurances as to whether or when the Offering may be completed or as to the actual size or terms of the Offering. A registration statement relating to these Securities has been filed with the SEC but has not yet become effective. These Securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these Securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the Securities laws of any such state or jurisdiction.
- ends -
Enquiries:
Thomas A. Nicolette, President and CEO | Tel. +1 856 848 8698 |
Antony Legge / James Thomas Daniel Stewart (Nomad and Broker) Ben Simons Vigo Communications
| Tel. +44 (0)20 7776 6550
Tel. +44 (0)20 7016 9574
|
Daniel Stewart & Company PLC is not acting for the Company in respect of the Offering
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com